The stock of Tissue Regenix Group PLC (LON:TRX) gapped up by GBX 0.013 today and has GBX 17.70 target or 3.00% above today’s GBX 17.18 share price. The 8 months technical chart setup indicates low risk for the GBX 129.11M company. The gap was reported on Nov, 29 by Barchart.com. If the GBX 17.70 price target is reached, the company will be worth GBX 3.87 million more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock increased 1.09% or GBX 0.18 on November 29, hitting GBX 17.18. About 225,422 shares traded hands or 6.44% up from the average. Tissue Regenix Group PLC (LON:TRX) has declined 13.92% since May 2, 2016 and is downtrending. It has underperformed by 19.18% the S&P500.
Tissue Regenix Group PLC (LON:TRX) Ratings Coverage
Out of 2 analysts covering Tissue Regenix Group PLC (LON:TRX), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Tissue Regenix Group PLC has been the topic of 15 analyst reports since October 12, 2015 according to StockzIntelligence Inc. Jefferies maintained Tissue Regenix Group PLC (LON:TRX) rating on Monday, January 18. Jefferies has “Buy” rating and GBX 36 price target. Beaufort Securities maintained the stock with “Speculative Buy” rating in Friday, September 2 report. The company was maintained on Thursday, March 10 by Beaufort Securities. Beaufort Securities maintained the shares of TRX in a report on Tuesday, July 12 with “Speculative Buy” rating. The rating was maintained by Jefferies with “Buy” on Wednesday, December 16. The firm has “Speculative Buy” rating given on Thursday, January 21 by Beaufort Securities. On Tuesday, May 24 the stock rating was maintained by Jefferies with “Buy”. On Monday, December 7 the stock rating was maintained by Beaufort Securities with “Speculative Buy”. The stock has “Speculative Buy” rating given by Beaufort Securities on Tuesday, May 24. As per Monday, July 4, the company rating was maintained by Beaufort Securities.
More important recent Tissue Regenix Group PLC (LON:TRX) news were published by: Uk.Finance.Yahoo.com which released: “Tissue Regenix Group Plc (TRX.L)” on March 30, 2014, also Businesswire.com published article titled: “Tissue Regenix Group plc: DermaPure® – Two Peer Reviewed Clinical Papers Published”, Fool.Co.Uk published: “Are GlaxoSmithKline plc, Tissue Regenix Group plc and Optibiotix Health plc …” on May 23, 2016. More interesting news about Tissue Regenix Group PLC (LON:TRX) was released by: Businesswire.com and their article: “Pioneering global regenerative medical technology company, Tissue Regenix …” with publication date: May 13, 2016.
Tissue Regenix Group plc is a medical technology company. The company has a market cap of 129.11 million GBP. The Firm is engaged in the development of regenerative products to make replacement native tissue using biological tissues. It currently has negative earnings. It operates through Cardiac, Wound Care and Orthopaedics divisions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.